Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
EQS Group
Biophytis / Key word(s): Miscellaneous
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in..
Biophytis / Key word(s): Miscellaneous
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in..
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene..
February 28, 2024
At #ECR2024, company also debuting Europe’s first mobile virtually helium-free MRI..